Mirati Therapeutics Inc (MRTX.OQ)
16 Mar 2018
BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION
* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs
* Mirati Therapeutics reports third quarter 2017 financial results
BRIEF-Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients
* Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients Source text for Eikon: Further company coverage:
- Mirati Therapeutics (MRTX) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
- Mirati Therapeutics (MRTX) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
- ROTY Volume 1 Edition 83: Thank You For Your Patience - Launch Day Has Arrived!
- ROTY Edition 1 Volume 82: Launch Preview And Adding To A Position
- ROTY Edition 1 Volume 81: We Have A Launch Date!
- Biotechs: Still Well Placed For More Gains